Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

20102,133 citationsJournal Article

Authors

Partnerships for the goals

Published in: The Lancet Oncology

Volume 11, Issue 8, pp. 753-762

Field-Weighted Citation Impact: 69.20